The original success of Sildenafil undeniably transformed the pharmaceutical landscape, but placing funds in companies strongly reliant on off-patent versions presents a challenging picture. Despite early earnings were impressive, the cessation of patents and the emergence of cheaper alternatives have eroded market share. Consequently, a thorough a